OPKO Health, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Phillip Frost
- Full Time Employees
- 2,997
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4400 Biscayne Boulevard Miami FL United States of America 33137
- IPO Date
- Nov 2, 1995
- CIK
- 0000944809
- Website
- opko.com
- Similar Companies
- Business
- OPKO Health, Inc. is a diversified healthcare company engaged primarily in the development and commercialization of pharmaceuticals, diagnostics, and nutritional products. The company offers an extensive portfolio that includes branded and generic pharmaceuticals; innovative diagnostic products and services, including laboratory testing; and nutritional products targeting cardiovascular, metabolic, and other health conditions. Core products include eye care pharmaceuticals such as Rayaldee for secondary hyperparathyroidism; bio-analytical testing services through its CLIA-certified laboratories; and novel therapeutics in oncology, endocrinology, and infectious diseases. OPKO also develops and markets vitamin and supplement lines. OPKO operates globally with significant presence in the United States, Latin America, and Europe, serving a broad range of customers including healthcare providers, hospitals, and consumers. Founded in 2007 and headquartered in Miami, Florida, the company continues to expand its footprint by leveraging its proprietary technologies and strategic partnerships. In the last 1-2 years, OPKO has focused on strategic expansion through key acquisitions and partnerships, aimed at enhancing its diagnostics capabilities and diversifying its pharmaceutical pipeline. Notably, it has launched several new diagnostic tests to capitalize on growing demand for advanced laboratory services. The company has also pursued collaborations with biotechnology firms to accelerate development of innovative therapeutics. Additionally, OPKO maintains active efforts to streamline operations and optimize its product portfolio to align with evolving market needs. Overall, OPKO Health stands as an integrated healthcare enterprise with operations spanning pharmaceuticals, diagnostics, and nutrition, with recent strategic initiatives reflecting its commitment to innovation and growth in multiple therapeutic and diagnostic domains.
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Financial Survey: OrthoPediatrics (NASDAQ:KIDS) and OPKO Health (NASDAQ:OPK)
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
Comparing OPKO Health (NASDAQ:OPK) & ADM Tronics Unlimited (OTCMKTS:ADMT)
OPKO Health, Inc. (NASDAQ:OPK) Receives $1.55 Consensus Price Target from Analysts
Reviewing PROCEPT BioRobotics (NASDAQ:PRCT) & OPKO Health (NASDAQ:OPK)
Analysts Set OPKO Health, Inc. (NASDAQ:OPK) Target Price at $2.03
Here's Why You Should Hold OPK Stock in Your Portfolio for Now